Across TCGA pan-cancer cohorts, TRBV20-1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TRBV20-1 data layer compared with 25 for mass-spec protein.
The strongest signal is observed in sarcoma (SARC), where higher TRBV20-1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRBV20-1 expression acts as an unfavorable survival marker.
SARC, GBM, and UCEC are the cancer types where TRBV20-1 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.